In real-world studies, the population meeting the criteria for ribociclib treatment accounted for 41.3–42.9% of HR+/HER2- early-stage breast cancers, the population meeting the criteria for abemaciclib treatment accounted for 17.5–18.1%, and the NATALEE study enrolled larger T1N1, T2N0, and T2N1 populations relative to monarchE. The gene discussed is HR; the disease is breast cancer.